307 related articles for article (PubMed ID: 27029491)
1. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
[TBL] [Abstract][Full Text] [Related]
2. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.
Rasche L; Duell J; Castro IC; Dubljevic V; Chatterjee M; Knop S; Hensel F; Rosenwald A; Einsele H; Topp MS; Brändlein S
Haematologica; 2015 Mar; 100(3):377-84. PubMed ID: 25637055
[TBL] [Abstract][Full Text] [Related]
3. The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.
Rasche L; Duell J; Morgner C; Chatterjee M; Hensel F; Rosenwald A; Einsele H; Topp MS; Brändlein S
PLoS One; 2013; 8(5):e63414. PubMed ID: 23667612
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
[TBL] [Abstract][Full Text] [Related]
7. The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78.
Rosenes Z; Mulhern TD; Hatters DM; Ilag LL; Power BE; Hosking C; Hensel F; Howlett GJ; Mok YF
PLoS One; 2012; 7(9):e44927. PubMed ID: 23028685
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
9. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
[TBL] [Abstract][Full Text] [Related]
10. Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Oka S; Ono K; Nohgawa M
J Clin Pharm Ther; 2018 Dec; 43(6):914-917. PubMed ID: 29974481
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
Benson DM; Cohen AD; Jagannath S; Munshi NC; Spitzer G; Hofmeister CC; Efebera YA; Andre P; Zerbib R; Caligiuri MA
Clin Cancer Res; 2015 Sep; 21(18):4055-61. PubMed ID: 25999435
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab combination prolongs myeloma survival.
Das M
Lancet Oncol; 2016 Oct; 17(10):e422. PubMed ID: 27601427
[No Abstract] [Full Text] [Related]
14. Early development of PAT-SM6 for the treatment of melanoma.
Hensel F; Eckstein M; Rosenwald A; Brändlein S
Melanoma Res; 2013 Aug; 23(4):264-75. PubMed ID: 23728394
[TBL] [Abstract][Full Text] [Related]
15. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T; Eid JE; Houp J; Gause C; Vuocolo S; Anderson KC
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):329-334.e1. PubMed ID: 27025160
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
17. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Richardson PG; Beksaç M; Špička I; Mikhael J
Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous binding of the anti-cancer IgM monoclonal antibody PAT-SM6 to low density lipoproteins and GRP78.
Rosenes Z; Mok YF; Yang S; Griffin MD; Mulhern TD; Hatters DM; Hensel F; Howlett GJ
PLoS One; 2013; 8(4):e61239. PubMed ID: 23620733
[TBL] [Abstract][Full Text] [Related]
19. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
Gross Z; Rahbari A; Wirtschafter E; Spektor TM; Udd KA; Bujarski S; Ghermezi M; Nosrati JD; Vidisheva A; Eades B; Cecchi G; Maluso T; Swift R; Berenson JR
Eur J Haematol; 2018 Jun; 100(6):621-623. PubMed ID: 29524348
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Wudhikarn K; Wills B; Lesokhin AM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]